3SBio's shares surged 32% to 19.18 Hong Kong dollars, equivalent to US$2.45, on Tuesday after the Chinese company said it would receive an upfront payment of US$1.25 billion and potential milestone ...

Chinese biotech company 3SBio's shares surged early Tuesday after its around US$6 billion licensing deal with Pfizer to develop, manufacture and commercialize a promising cancer drug. Shares were up ...

Contrarian investing advice from biotech and pharmaceutical stock expert Hartaj Singh, Founding Partner of Tecumseh Partners ...

The FDA is changing how drugs get approved—and that could unleash a biotech revolution. Dylan Jovine from Behind the Markets shares 4 biotech companies on the verge of explosive breakthroughs, ...

BioNTech's BNT324 aims to outpace rivals in cancer treatment with its unique bispecific antibody design. Read more here.

Two excellent candidates are Vertex Pharmaceuticals ( VRTX -1.05%) and Axsome Therapeutics ( AXSM -1.06%). Here's what makes ...

If Recursion Pharmaceuticals can achieve its goal of cutting the time and money it takes to develop drugs by meaningful ...

Investors who picked the bottom of the recent large cap biotech rout have snared enviable ... imaging giant Pro Medicus (ASX:PME), the stock has declined 7% year to date. Yet astute investors ...

“By identifying opportunities to bring in stable revenue, we believe the Company can reduce its need for capital that could be dilutive to the stock price,” Latkin said. The real estate ...

The stock has dropped nearly 30% year-to-date and remains unprofitable post-purchase. ⚈ Delaney’s committee roles suggest potential informational advantages in biotech-related decisions. Finbold’s ...

ADAPTIVE BIOTECH ($ADPT) posted quarterly earnings results on Thursday, May 1st. The company reported earnings of -$0.20 per share, beating estimates of -$0.30 by $0. ...